Priority Action in Anaphylaxis
The correct answer is
administer epinephrine 0.3-0.5 mg intramuscularly. In the setting of anaphylaxis, a severe and rapidly progressing hypersensitivity reaction, the physiological priority is to reverse the life-threatening effects of massive vasodilation, increased vascular permeability, and bronchoconstriction. Epinephrine is the first-line pharmacological intervention because it directly counteracts these mechanisms through its alpha- and beta-adrenergic agonist properties. Alpha-1 agonism causes vasoconstriction, which elevates blood pressure, reduces laryngeal and airway edema, and decreases urticaria. Beta-1 agonism increases cardiac contractility and heart rate, supporting cardiac output, while beta-2 agonism induces bronchodilation, relieving respiratory distress and wheezing. The intramuscular route into the anterolateral thigh is preferred for its rapid and predictable absorption in a hemodynamically unstable patient, where establishing intravenous access can be difficult and time-consuming
[2]. Delaying epinephrine administration to first start an IV line, administer a second-line agent like an antihistamine, or reposition the client can allow the anaphylactic cascade to progress to airway obstruction and cardiovascular collapse. The clinical urgency of anaphylaxis mirrors the time-sensitive nature of other critical events, such as cardiac arrest, where epinephrine is also a key first-line medication to support perfusion and the return of spontaneous circulation
[2]. While the provided evidence focuses on penicillin allergy management and the critical role of epinephrine in resuscitation, the foundational principle remains that in anaphylaxis, immediate epinephrine administration is the single most critical action to prevent mortality.
References (research sources)
- [2]
Evaluating intramuscular epinephrine in pediatric out-of-hospital cardiac arrest (the PRIME trial): study protocol for a multi-centre, stepped-wedge cluster quasi-randomized controlled trial.RCT/clinical trialIdrees S, Assaf M, Davis M, Garcia-Bournissen F, Loosley J, Miller MR, Tijssen JA. (2026) · DOI: 10.1186/s13063-026-09776-3